Solvias announced today that it is expanding its global network of laboratory testing centres with a new biotech site in Research Triangle Park, N.C. It is the company’s latest investment to expand its analytical testing services supporting life science organisations with the growing number of cell and gene therapies (CGTs) and biologics in use and under development.
The 50,000-square-foot facility, expected to be completed in 2025 and bring 170+ jobs to the Raleigh-Durham area, will serve as Solvias’ North American hub for large molecule analytical services. It will offer critical cell-based potency assays, advanced Next-Gen Sequencing (NGS) capabilities, and related testing services supporting multiple biologic modalities. From the outset, the new testing centre will support characterisation and release testing of CGT and other advanced therapies, including Adeno-Associated virus (AAV) gene therapies, mRNA therapies and antibody drug conjugates.
Noting that the global CGT and advanced biologics market is expected to maintain a double-digit annual growth rate over the next ten years, Archie Cullen, CEO of Solvias, said: “Our new centre strongly complements our biologics and CGT sites in Europe and expands our world-class testing capabilities in the U.S. Our team is thrilled to bring our newest centre of excellence to Research Triangle Park, a leading research and development centre and burgeoning hub for the life science industry. We will continue to invest in expanding our capabilities to support our customers with their critical work of developing and maintaining life-changing therapies.”
Solvias’ new facility expands its global footprint to six centres of excellence. It is the company’s second site in the U.S., where it supports life science organisations with analytical testing. The new centre will feature state-of-the-art analytical instrumentation, laboratory automation technology and integrated digital management systems.